🇺🇸 DALFAMPRIDINE in United States

7,465 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fall — 1,239 reports (16.6%)
  2. Gait Disturbance — 1,106 reports (14.82%)
  3. Drug Ineffective — 957 reports (12.82%)
  4. Fatigue — 843 reports (11.29%)
  5. Multiple Sclerosis Relapse — 615 reports (8.24%)
  6. Balance Disorder — 600 reports (8.04%)
  7. Covid-19 — 582 reports (7.8%)
  8. Multiple Sclerosis — 539 reports (7.22%)
  9. Asthenia — 492 reports (6.59%)
  10. Dizziness — 492 reports (6.59%)

Source database →

DALFAMPRIDINE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is DALFAMPRIDINE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for DALFAMPRIDINE in United States?

Marketing authorisation holder not available in our data.